Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

21. Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care

Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Canadian Cardiovascular Harmonized National Guidelines Endeavour (C (...) -CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update Sheldon W. Tobe , James A. Stone , Todd Anderson , Simon Bacon , Alice Y.Y. Cheng , Stella S. Daskalopoulou , Justin A. Ezekowitz , Jean C. Gregoire , Gord Gubitz , Rahul Jain , Karim Keshavjee , Patty Lindsay , Mary L’Abbe , David C.W. Lau , Lawrence A. Leiter , Eileen O’Meara , Glen J. Pearson , Doreen M. Rabi , Diana Sherifali , Peter Selby , Jack V. Tu , Sean Wharton , Kimberly M. Walker

CMA Infobase (Canada)2018

22. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular (...) death, myocardial infarction, or stroke. METHODS: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30-50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used

Lancet2018

23. Tai Chi exercise is more effective than brisk walking in reducing cardiovascular disease risk factors among adults with hypertension: A randomised controlled trial

Tai Chi exercise is more effective than brisk walking in reducing cardiovascular disease risk factors among adults with hypertension: A randomised controlled trial 30195124 2018 10 10 1873-491X 88 2018 Aug 24 International journal of nursing studies Int J Nurs Stud Tai Chi exercise is more effective than brisk walking in reducing cardiovascular disease risk factors among adults with hypertension: A randomised controlled trial. 44-52 S0020-7489(18)30201-3 10.1016/j.ijnurstu.2018.08.009 Physical (...) inactivity is a major modifiable lifestyle risk factor associated with cardiovascular disease. Tai Chi is a safe and popular form of physical activity among older adults, yet direct comparisons are lacking between Tai Chi and brisk walking in their ability to reduce cardiovascular disease risk factors and improve psychosocial well-being. 246 adults (mean age = 64.4 ± 9.8 years, age range = 30-91 years, 45.5% men) with hypertension and at least two but not more than three modifiable cardiovascular disease

EvidenceUpdates2018

24. Editorial: Extracellular Vesicle-Mediated Processes in Cardiovascular Diseases

Editorial: Extracellular Vesicle-Mediated Processes in Cardiovascular Diseases 30283791 2018 12 19 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Editorial: Extracellular Vesicle-Mediated Processes in Cardiovascular Diseases. 133 10.3389/fcvm.2018.00133 Koenen Rory R RR Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands. Aikawa Elena E Cardiovascular Division, Department of Medicine, Center

Frontiers in cardiovascular medicine2018 Full Text: Link to full Text with Trip Pro

25. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study.

Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. BACKGROUND: Dietary guidelines recommend minimising consumption of whole-fat dairy products, as they are a source of saturated fats and presumed to adversely affect blood lipids and increase cardiovascular disease and mortality. Evidence for this contention is sparse and few data for the effects of dairy consumption on health are available from (...) low-income and middle-income countries. Therefore, we aimed to assess the associations between total dairy and specific types of dairy products with mortality and major cardiovascular disease. METHODS: The Prospective Urban Rural Epidemiology (PURE) study is a large multinational cohort study of individuals aged 35-70 years enrolled from 21 countries in five continents. Dietary intakes of dairy products for 136 384 individuals were recorded using country-specific validated food frequency questionnaires

Lancet2018

26. Management of Cardiovascular Diseases during Pregnancy

Management of Cardiovascular Diseases during Pregnancy We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy | European Heart Journal | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close (...) mobile search navigation Article navigation 07 September 2018 Article Contents Article Navigation 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy Vera Regitz-Zagrosek Chairperson Corresponding authors. Vera Regitz-Zagrosek, Charité Universitaetsmedizin Berlin, Institute for Gender in Medicine, CCR, DZHK, partner site Berlin, Hessische Str 3-4, 10115 Berlin, Germany, Tel: +49 30 450 525 288, Fax: +49 30 450 7 525 288, E-mail: . Search for other works by this author

European Society of Cardiology2018

27. Environmental toxic metal contaminants and risk of cardiovascular disease: systematic review and meta-analysis.

Environmental toxic metal contaminants and risk of cardiovascular disease: systematic review and meta-analysis. OBJECTIVE: To conduct a systematic review and meta-analysis of epidemiological studies investigating the association of arsenic, lead, cadmium, mercury, and copper with cardiovascular disease. DESIGN: Systematic review and meta-analysis. DATA SOURCES: PubMed, Embase, and Web of Science searched up to December 2017. REVIEW METHODS: Studies reporting risk estimates for total (...) cardiovascular disease, coronary heart disease, and stroke for levels of arsenic, lead, cadmium, mercury, or copper were included. Two investigators independently extracted information on study characteristics and outcomes in accordance with PRISMA and MOOSE guidelines. Relative risks were standardised to a common scale and pooled across studies for each marker using random effects meta-analyses. RESULTS: The review identified 37 unique studies comprising 348 259 non-overlapping participants, with 13 033

BMJ2018 Full Text: Link to full Text with Trip Pro

28. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. BACKGROUND: The use of aspirin in the primary prevention of cardiovascular events remains controversial. We aimed to assess the efficacy and safety of aspirin versus placebo in patients with a moderate estimated risk of a first cardiovascular event. METHODS: ARRIVE is a randomised, double-blind, placebo-controlled (...) , multicentre study done in seven countries. Eligible patients were aged 55 years (men) or 60 years (women) and older and had an average cardiovascular risk, deemed to be moderate on the basis of the number of specific risk factors. We excluded patients at high risk of gastrointestinal bleeding or other bleeding, or diabetes. Patients were randomly assigned (1:1) with a computer-generated randomisation code to receive enteric-coated aspirin tablets (100 mg) or placebo tablets, once daily. Patients

Lancet2018

29. Extracellular Vesicles as Biomarkers in Cardiovascular Disease; Chances and Risks

Extracellular Vesicles as Biomarkers in Cardiovascular Disease; Chances and Risks 30186839 2018 11 14 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Extracellular Vesicles as Biomarkers in Cardiovascular Disease; Chances and Risks. 113 10.3389/fcvm.2018.00113 The field of extracellular vesicles (EV) is rapidly expanding, also within cardiovascular diseases. Besides their exciting roles in cell-to-cell communication, EV have the potential to serve as excellent (...) biomarkers, since their counts, content, and origin might provide useful information about the pathophysiology of cardiovascular disorders. Various studies have already indicated associations of EV counts and content with cardiovascular diseases. However, EV research is complicated by several factors, most notably the small size of EV. In this review, the advantages and drawbacks of EV-related methods and applications as biomarkers are highlighted. Dickhout Annemiek A Department of Biochemistry

Frontiers in cardiovascular medicine2018 Full Text: Link to full Text with Trip Pro

30. Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study.

Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. BACKGROUND: WHO recommends that populations consume less than 2 g/day sodium as a preventive measure against cardiovascular disease, but this target has not been achieved in any country. This recommendation is primarily based on individual-level data from short-term trials of blood pressure (BP) without data relating low sodium intake to reduced (...) cardiovascular events from randomised trials or observational studies. We investigated the associations between community-level mean sodium and potassium intake, cardiovascular disease, and mortality. METHODS: The Prospective Urban Rural Epidemiology study is ongoing in 21 countries. Here we report an analysis done in 18 countries with data on clinical outcomes. Eligible participants were adults aged 35-70 years without cardiovascular disease, sampled from the general population. We used morning fasting

Lancet2018

31. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.

Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. BACKGROUND: People with type 1 diabetes are at elevated risk of mortality and cardiovascular disease, yet current guidelines do not consider age of onset as an important risk stratifier. We aimed to examine how age at diagnosis of type 1 diabetes relates to excess mortality and cardiovascular risk. METHODS: We did a nationwide, register-based (...) cohort study of individuals with type 1 diabetes in the Swedish National Diabetes Register and matched controls from the general population. We included patients with at least one registration between Jan 1, 1998, and Dec 31, 2012. Using Cox regression, and with adjustment for diabetes duration, we estimated the excess risk of all-cause mortality, cardiovascular mortality, non-cardiovascular mortality, acute myocardial infarction, stroke, cardiovascular disease (a composite of acute

Lancet2018

32. Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials

Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials 29802688 2018 07 02 1463-1326 2018 May 26 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. 10.1111/dom.13384 Individuals with both diabetes mellitus (DM) and atherosclerotic cardiovascular disease (...) , Sanofi, Chilly-Mazarin, France. IviData Stats, Levallois-Perret, France. Letierce Alexia A Biostatistics and Programming, Sanofi, Chilly-Mazarin, France. Leiter Lawrence A LA http://orcid.org/0000-0002-1040-6229 Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. eng Journal Article 2018 05 26 England Diabetes Obes Metab 100883645 1462-8902 cardiovascular disease clinical trial dyslipidaemia lipid-lowering therapy 2018 03 29 2018 05 14 2018 05 23

EvidenceUpdates2018

33. Cardiovascular Disease: Secondary Prevention

Cardiovascular Disease: Secondary Prevention © 1996 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 0 Atherosclerotic Cardiovascular Disease (ASCVD) Secondary Prevention Guideline Major Changes as of April 2018 2 Definitions 2 Target Population 2 Goals 2 Lifestyle Modifications 3 Dietary Supplements 4 Influenza Vaccination 4 Statin Therapy 4 ACE Inhibitor or ARB Therapy 9 Antiplatelet Therapy 9 Lowering Triglycerides to Prevent Pancreatitis 10 Beta-blocker Therapy for Post (...) GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016 Nov;32(11):1263-1282. Catapano AL, Graham I, De Backer G, et al for the Authors/Task Force Members. 2016 ESC/EAS Guidelines for the Management of Dyslipidemias: The Task Force for the Management of Dyslipidemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special

Kaiser Permanente Clinical Guidelines2018

34. Cardiovascular Disease: Primary Prevention

Cardiovascular Disease: Primary Prevention © 1996 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 Atherosclerotic Cardiovascular Disease (ASCVD) Primary Prevention Guideline Major Changes as of April 2018 2 Definitions 3 Goals of Primary Prevention 3 Lipid Screening and ASCVD Risk Calculation 3 Lifestyle Modifications 5 Dietary Supplements 6 Statin Therapy 7 Shared decision making: ASCVD risk tool 10 Antiplatelet Therapy 12 Patients with Diabetes: ACE Inhibitor or ARB (...) of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016 Nov; 32(11):1263- 1282. Bhatt DL, Scheiman J, Abraham NS, Antman EM, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52:1502-1517. Bibbins-Domingo K for the U.S. Preventive Services Task Force. Aspirin Use

Kaiser Permanente Clinical Guidelines2018

35. Cardiovascular disease

Cardiovascular disease Top results for cardiovascular disease - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top (...) search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for cardiovascular disease The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection

Trip Latest and Greatest2018

36. Remote ECG interpretation consultancy services for cardiovascular disease

Remote ECG interpretation consultancy services for cardiovascular disease Remote ECG interpretation consultancy services Remote ECG interpretation consultancy services for cardio for cardiovascular disease vascular disease Medtech innovation briefing Published: 27 July 2018 nice.org.uk/guidance/mib152 pathways Summary Summary The technologies technologies described in this briefing are remote electrocardiogram (ECG) interpretation consultancy services. They are used for assisting in diagnosing (...) and decision-making for people with cardiovascular disease. The inno innovativ vative aspects e aspects are that with remote ECG interpretation, a person does not need to travel to hospital for a consultation with a cardiologist, potentially providing quicker and more accurate diagnoses. The intended place in ther place in therap apy y would be to replace referrals to secondary care for interpreting ECGs from people with suspected cardiovascular disease. The main points from the e main points from

National Institute for Health and Clinical Excellence - Advice2018

37. Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT)

Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT) 30037888 2018 07 27 1488-2329 190 29 2018 Jul 23 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT). E871-E882 10.1503 (...) /cmaj.170914 Routinely collected data from large population health surveys linked to chronic disease outcomes create an opportunity to develop more complex risk-prediction algorithms. We developed a predictive algorithm to estimate 5-year risk of incident cardiovascular disease in the community setting. We derived the Cardiovascular Disease Population Risk Tool (CVDPoRT) using prospectively collected data from Ontario respondents of the Canadian Community Health Surveys, representing 98

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

38. Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register

Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register 30002197 2018 08 15 1935-5548 2018 Jul 12 Diabetes care Diabetes Care Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. dc180578 10.2337/dc18-0578 To evaluate the performance of five cardiovascular disease (CVD (...) ) risk scores developed in diabetes populations and compare their performance to QRISK2. A cohort of people diagnosed with type 2 diabetes between 2004 and 2016 was identified from the Scottish national diabetes register. CVD events were identified using linked hospital and death records. Five-year risk of CVD was estimated using each of QRISK2, ADVANCE, Cardiovascular Healthy Study (CHS), New Zealand Diabetes Cohort Study (NZ DCS), Fremantle Diabetes Study, and Swedish National Diabetes Register

EvidenceUpdates2018

39. Prediction of cardiovascular disease among hematopoietic cell transplantation survivors

Prediction of cardiovascular disease among hematopoietic cell transplantation survivors 30037802 2018 11 14 2473-9537 2 14 2018 Jul 24 Blood advances Blood Adv Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. 1756-1764 10.1182/bloodadvances.2018019117 Cardiovascular disease (CVD) is a leading cause of late morbidity and mortality in hematopoietic cell transplantation (HCT) survivors. HCT-specific CVD risk prediction models are needed to facilitate early (...) screening and prevention. In the current study, patients who underwent HCT at City of Hope (COH) and survived 1-year free of clinically evident CVD (N = 1828) were observed for the development of heart failure (HF) or coronary artery disease (CAD) by 10-years from index date (1 year from HCT). CVD occurred in 135 individuals (92 HF, 43 CAD). Risk prediction models were developed for overall CVD (HF and/or CAD) using COH-derived integer risk scores. Risk scores based on selected variables (age

Blood advances2018 Full Text: Link to full Text with Trip Pro

40. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.

Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. BACKGROUND: This is the first update of the review published in 2017. Hypertension is a prominent preventable cause of premature morbidity and mortality. People with hypertension and established cardiovascular disease are at particularly high risk, so reducing blood pressure to below standard targets may be beneficial. This strategy could reduce cardiovascular mortality and morbidity but could also (...) increase adverse events. The optimal blood pressure target in people with hypertension and established cardiovascular disease remains unknown. OBJECTIVES: To determine if 'lower' blood pressure targets (≤ 135/85 mmHg) are associated with reduction in mortality and morbidity as compared with 'standard' blood pressure targets (≤ 140 to 160/90 to 100 mmHg) in the treatment of people with hypertension and a history of cardiovascular disease (myocardial infarction, angina, stroke, peripheral vascular

Cochrane2018